PT-141 vs Melanotan II
PT-141 and Melanotan II are both melanocortin peptides that affect sexual function, but PT-141 was specifically developed to isolate the sexual response from Melanotan II's broader effects. Melanotan II causes tanning, appetite suppression, and sexual arousal; PT-141 targets sexual function only. This comparison covers the practical differences and safety considerations between them.
PT-141 (Vyleesi) is a prescription medication. Melanotan II is an unapproved research peptide. This comparison is for educational purposes only and does not constitute medical advice.
How PT-141 Works
PT-141 (bremelanotide) is a cyclic heptapeptide that selectively activates the MC4R (melanocortin-4 receptor) in the central nervous system. MC4R activation in the hypothalamus modulates dopaminergic and oxytocinergic pathways involved in sexual desire and arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act on blood flow, PT-141 works centrally on the brain's desire circuitry.
PT-141 was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is administered as a 1.75mg subcutaneous injection at least 45 minutes before anticipated sexual activity. Clinical trials demonstrated statistically significant improvements in sexual desire and reduction in distress related to low sexual desire. PT-141 does not significantly activate MC1R (tanning) or MC3R/MC5R, giving it a cleaner side effect profile than Melanotan II.
How Melanotan II Works
Melanotan II is a non-selective melanocortin peptide analog that activates multiple melanocortin receptors — MC1R through MC5R. Its broad receptor activation produces multiple simultaneous effects: MC1R activation stimulates melanocytes to produce melanin (tanning), MC4R activation triggers sexual arousal, MC3R/MC4R activation in the hypothalamus suppresses appetite, and MC5R activation affects exocrine gland function.
Melanotan II is not approved for human use in any country. It is primarily used for its tanning effects, with the sexual function enhancement considered a secondary benefit. Research doses typically range from 0.25-1mg subcutaneously, often starting with a loading phase of daily injections followed by maintenance dosing. Its non-selective receptor binding produces a wider range of side effects including nausea, facial flushing, darkening of moles and freckles, and in rare cases, changes in existing nevi that warrant dermatological monitoring.
Key Differences
The critical difference is receptor selectivity. PT-141 preferentially activates MC4R for sexual function while largely sparing MC1R (tanning) and other melanocortin receptors. Melanotan II activates all melanocortin receptors non-selectively, producing a bundle of effects — tanning, sexual arousal, appetite suppression, and nausea — that cannot be separated from each other.
The regulatory status differs fundamentally. PT-141 has completed Phase III clinical trials, has a characterized safety profile, and is FDA-approved. Melanotan II has no regulatory approval anywhere and lacks the systematic safety evaluation that comes with the drug approval process. The dermatological concerns with Melanotan II are particularly notable — long-term MC1R stimulation raises questions about melanoma risk that have not been adequately studied.
For users specifically seeking sexual function enhancement, PT-141 is the targeted tool without the unwanted tanning, appetite changes, and broader side effects of Melanotan II. For users who specifically want the tanning effect (with sexual function as a bonus), Melanotan II is the only option — but it comes with a broader and less characterized risk profile. PT-141's common side effects are nausea (in about 40% of users), flushing, and headache, which are transient.
Side-by-Side Comparison
| Feature | PT-141 | Melanotan II |
|---|---|---|
| Mechanism | Selective MC4R agonist (sexual function) | Non-selective MC1R-MC5R agonist (tanning + sexual + appetite) |
| Primary Use | Sexual desire enhancement | Skin tanning, sexual function, appetite suppression |
| Dosage Range | 1.75mg subcutaneous (as needed) | 0.25–1mg subcutaneous (loading + maintenance) |
| Onset Time | 45 min–2 hours | 1–2 hours (sexual); days–weeks (tanning) |
| Side Effects | Nausea (~40%), flushing, headache | Nausea, flushing, mole darkening, appetite loss |
| Evidence Level | FDA-approved (Phase III trials) | Early clinical data, not approved anywhere |
| Cost (per dose) | $30–$50 (prescription) | $1–$3 (research peptide) |
When to Choose PT-141 vs Melanotan II
Choose PT-141 when sexual function enhancement is the specific goal and you want a compound with FDA approval, characterized safety data, and minimal off-target effects. Its selective MC4R action provides sexual function benefits without skin color changes or appetite suppression.
Melanotan II is used by those who specifically want the tanning effect, with sexual enhancement as an additional benefit. However, its lack of regulatory approval, broader side effect profile, and dermatological concerns (mole darkening, potential melanoma considerations) make it a higher-risk choice. Users should have regular dermatological monitoring if using Melanotan II.
Can You Stack PT-141 and Melanotan II?
Stacking PT-141 and Melanotan II is not recommended. Both activate MC4R, and combining them would produce excessive melanocortin signaling with no synergistic benefit — only increased side effects (particularly nausea and flushing). If the goal is sexual function alone, PT-141 is sufficient. If both tanning and sexual effects are desired, Melanotan II provides both in a single compound, making the addition of PT-141 redundant.
Related Reading
- Best Peptides for Libido — peptides that support sexual health
- Are Peptides Safe? — understanding peptide safety profiles
- How to Use Peptides — practical guide to peptide protocols
- What Are Peptides? — introduction to research peptides
Frequently Asked Questions
Is PT-141 FDA approved?
Yes. PT-141 (Vyleesi) was FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. It is the only melanocortin-based sexual function drug with FDA approval. Melanotan II has no regulatory approval.
Does Melanotan II actually work for tanning?
Yes, it stimulates melanin production through MC1R activation. Clinical studies confirm increased pigmentation. However, tanning is often uneven and can darken moles, raising dermatological concerns. It is not approved for this use.
Which has fewer side effects?
PT-141 has fewer side effects due to its selective MC4R targeting. Melanotan II activates multiple receptors causing a broader range of effects including skin darkening, appetite suppression, and mole changes beyond the shared nausea and flushing.
Can PT-141 cause skin darkening?
PT-141 has minimal effect on skin pigmentation because it does not significantly activate MC1R. Melanotan II strongly activates MC1R, producing noticeable darkening. This selectivity is the key design difference between them.
Further Reading & Research
Explore independent research databases and regulatory resources.
Medical Disclaimer: PT-141 is a prescription medication. Melanotan II is an unapproved research peptide. The information on this page is for educational purposes only and does not constitute medical advice.